#1 Clinical Trials Search in Europe

Study on the Effectiveness and Safety of Circumcision and Antibiotic Treatment (Cefaclor, Sulfamethoxazole, Trimethoprim) for Boys with Posterior Urethral Valves

2 1 1 1

What is this study about?

This clinical trial is focused on studying the effects of circumcision on the risk of febrile urinary tract infections (fUTIs) in boys with a condition called Posterior Urethral Valves (PUV). PUV is a blockage in the urinary tract that occurs in boys and can lead to urinary problems. The study aims to understand how circumcision alone, as well as in combination with antibiotic treatments, affects the likelihood of developing fUTIs over a period of two years.

In this study, the medications being used include ALFATIL, which contains the active substance cefaclor, Bactrim, which contains sulfamethoxazole and trimethoprim, and AUGMENTIN, which contains amoxicillin and clavulanic acid. These medications are all antibiotics, which are drugs used to treat bacterial infections. The trial will compare the effects of circumcision alone, circumcision with antibiotics, and antibiotics alone on the risk of fUTIs.

The study will follow participants over a two-year period to observe the time it takes for the first fUTI to occur, if at all. It will also look at the number of infections, any changes in kidney health, and the types of bacteria causing the infections. The goal is to determine the best approach to reduce the risk of fUTIs in boys with PUV, using historical data to enrich the findings. Participants will be monitored for their adherence to the antibiotic treatments and the overall effectiveness of the different approaches will be assessed.

1 joining the study

Upon joining the study, the child must be a male aged between 1 to 31 days. The child should have undergone a procedure called valve resection and circumcision before reaching one month of age.

The child’s guardians must be adults over 18 years old, affiliated with a social security system, and have signed an informed consent form allowing the child to participate in the study.

2 initial medical assessment

The child will undergo an initial medical assessment to confirm the diagnosis of posterior urethral valves through a procedure called cystography, which should have been completed within the first 28 days of life.

3 treatment and monitoring

The study aims to assess the effect of circumcision alone on the risk of febrile urinary tract infections (fUTIs) over a period of two years. The child may also receive antibiotic prophylaxis, which involves taking medication to prevent infections.

The medications used in the study include cefaclor, sulfamethoxazole with trimethoprim, and amoxicillin with clavulanic acid. These are administered orally in the form of a suspension, which is a liquid form of medication.

4 follow-up and evaluation

The primary goal is to monitor the time to the first febrile urinary tract infection from the start of the study until two years later. A febrile urinary tract infection is identified by a fever higher than 38.5 degrees Celsius, along with signs of infection in the urine.

Secondary evaluations include the number of infections over two years, changes in kidney scans, and the types of germs causing infections. The study will also explore factors that may increase the risk of infections and adherence to antibiotic treatment.

5 completion of the study

The study is expected to conclude by May 15, 2030. At the end of the study, the collected data will be analyzed to determine the effectiveness of circumcision alone, circumcision with antibiotics, and antibiotics alone in preventing febrile urinary tract infections.

Who Can Join the Study?

  • The child must be a male.
  • The child must be between 1 to 31 days old.
  • The child must have had a procedure called valve resection and circumcision before they are 1 month old.
  • The child must have been diagnosed with Posterior Urethral Valves using a test called cystography within the first 28 days of life.
  • The child’s parental guardians must be over 18 years old.
  • The child’s parental guardians must be part of a social security system.
  • The child’s parental guardians must have signed an informed consent form, which means they agree to let their child participate in the study.
  • For some groups, the child’s parental guardians must not be opposed to their child’s participation in the trial.
  • The child’s parental guardians giving consent must be able to understand the trial completely.

Who Cannot Join the Study?

  • Patients who are not male cannot participate in the study.
  • Patients who are not within the specified age range cannot participate. The study is for children only.
  • Patients who do not have Posterior Urethral Valves cannot participate. This is a condition affecting the urinary tract.
  • Patients who are considered part of a vulnerable population may not be eligible. This means groups who might need special protection or care.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Centre Hospitalier Universitaire De Bordeaux Bordeaux France
Oncopole Claudius Regaud Toulouse France

Other Sites

Site Name City Country Status
Centre Hospitalier Universitaire De La Reunion St Denis France
Centre Hospitalier Universitaire De Montpellier Montpellier France
Centre Hospitalier Universitaire De Nantes Nantes France
Centre Hospitalier Universitaire De Rennes Rennes France
Hopital Beaujon Clichy France
Clksfy Hoomihxvwpr Urdxaihvgsfcy Rxyqi Reims France
Cfnryd Habgxgqrqjq Ee Utziorvnpebic Dt Lkjslfc Limoges France
Aragkibsle Pktlqkii Hmjjfhya Dz Mpwceaxrl Marseille France
Blnijwuj Ukohkvpsea Hoenecua Cxoglj Besançon France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Not yet recruiting
15.05.2025

Trial locations

Investigated drugs:

Antibiotic Prophylaxis is a treatment approach where antibiotics are given to prevent infections before they occur. In this trial, the focus is on preventing febrile urinary tract infections in boys with a specific condition called posterior urethral valves. The antibiotics work by stopping bacteria from growing and causing an infection, which can help reduce the risk of these infections happening in the first place.

Investigated diseases:

Posterior Urethral Valves – Posterior Urethral Valves is a condition characterized by the presence of abnormal folds of tissue in the urethra of male infants, which obstructs the normal flow of urine. This obstruction can lead to a buildup of urine in the bladder, ureters, and kidneys, causing swelling and potential damage. Over time, the increased pressure can result in bladder dysfunction and kidney impairment. The condition is typically identified in infancy or early childhood. As the child grows, the severity of symptoms can vary, potentially leading to urinary tract infections and issues with kidney function. Regular monitoring and management are essential to address complications associated with this condition.

Trial ID:
2024-519166-48-01
Protocol code:
CHUBX 2023/52
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Study on Early Oxybutynin Treatment for Boys with Posterior Urethral Valves

    Recruiting

    2 1 1
    Investigated diseases:
    Investigated drugs:
    France